Israel backs NIS 70 million bio AI infrastructure consortium

Israel’s Innovation Authority is investing NIS 70 million in a national consortium to build shared infrastructure for AI models trained on biological data. The project brings together NVIDIA, Teva, Sheba Medical Center, startups and universities to speed drug discovery, personalized medicine and clinical decision-making.

Why it matters: - The consortium aims to build a shared infrastructure for bio AI, which could make biological data easier to standardize, combine and use across industry, academia and healthcare. - The initiative targets drug discovery, personalized medicine and clinical support, areas where better biological models could speed decisions and improve treatment matching. - The project is meant to give Israel a national platform in a field where computational biology still lacks a common data language.

What happened: - The Israel Innovation Authority announced a NIS 70 million investment in the Israel BioToken Factory Initiative, or IBFI. - The consortium brings together NVIDIA, Teva Pharmaceutical Industries, Sheba Medical Center, CytoReason, TerraCyte Analytics and MeMed. - Researchers from the Weizmann Institute of Science, the Technion – Israel Institute of Technology and Ben-Gurion University of the Negev are also involved. - The announcement was made in Jerusalem on July 12, 2026.

The details: - IBFI will develop a common technology platform for AI applications in biology, drug discovery and personalized medicine. - The shared infrastructure will have two core components: Bio Tokens and Factory Model. - Bio Tokens will provide a standardized representation layer for different types of biological data. - Factory Model will support the development, integration, execution and accessibility of AI-based biological models. - The platform is designed to connect molecular, cellular, dynamic and clinical data in a single computational framework. - The consortium’s initial applications are expected to include oncology treatment response prediction, immune system activity assessment, drug hypersensitivity prediction, sepsis decision support, transplant rejection assessment, autoimmune disease work and drug discovery. - The scientific work will be led by Prof. Eran Segal and Prof. Nir Yosef of the Weizmann Institute, Prof. Shai Shen-Orr of the Technion and Prof. Assaf Zaritsky of Ben-Gurion University. - The initiative is structured as a pre-competitive R&D infrastructure for the Israeli life sciences ecosystem.

Between the lines: - The investment reflects a broader push to build enabling infrastructure, not just individual AI products. - Dror Bin, CEO of the Israel Innovation Authority, said the harder problem is now the infrastructure that lets models learn from the complexity of human biology. - Gila Gamliel, Israel’s minister of innovation, science and technology, framed the project as a force multiplier across technology, pharma, hospitals and academia. - Yoav Nissan Cohen, chairman of the consortium and CEO and chairman of TerraCyte, said the goal is to create the “language” that biological AI needs to advance personalized medicine.

What’s next: - IBFI will move into developing its shared platform and validating early use cases. - The consortium is expected to expand the use of standardized biological data across research and clinical settings. - The Israel Innovation Authority said the effort fits its strategy of backing breakthrough technological infrastructure that links industry, academia and healthcare. - The authority expects the program to strengthen Israel’s position in artificial intelligence, biotechnology and personalized medicine over time.

The bottom line: - Israel is betting that shared bio-data infrastructure will be a foundational advantage in the next wave of AI-driven medicine.